Arbutus Biopharma (ABUS) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $905000.0.
- Arbutus Biopharma's Receivables - Net fell 4371.89% to $905000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $905000.0, marking a year-over-year decrease of 4371.89%. This contributed to the annual value of $2.4 million for FY2024, which is 3564.19% up from last year.
- Arbutus Biopharma's Receivables - Net amounted to $905000.0 in Q3 2025, which was down 4371.89% from $1.0 million recorded in Q2 2025.
- Arbutus Biopharma's 5-year Receivables - Net high stood at $2.7 million for Q1 2023, and its period low was $899000.0 during Q4 2021.
- Over the past 5 years, Arbutus Biopharma's median Receivables - Net value was $1.7 million (recorded in 2021), while the average stood at $1.7 million.
- As far as peak fluctuations go, Arbutus Biopharma's Receivables - Net skyrocketed by 10289.41% in 2023, and later plummeted by 4474.05% in 2025.
- Over the past 5 years, Arbutus Biopharma's Receivables - Net (Quarter) stood at $899000.0 in 2021, then skyrocketed by 50.39% to $1.4 million in 2022, then soared by 31.36% to $1.8 million in 2023, then surged by 35.64% to $2.4 million in 2024, then crashed by 62.43% to $905000.0 in 2025.
- Its last three reported values are $905000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.2 million during Q1 2025.